High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database-Reference-Cited by-同舟云学术

High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database

Published:2023-04 Issue: Volume:49 Page:100486
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Adachi Koichiro^ORCID,Ohyama Katsuhiro^ORCID,Tanaka Yoichi^ORCID,Sato Tasuku,Murayama Norie,Shimizu Makiko^ORCID,Saito Yoshiro^ORCID,Yamazaki Hiroshi^ORCID

Funder

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference37 articles.

1. U.S. FDA approved drugs from 2015–june 2020: a perspective;Bhutani;J Med Chem,2021

2. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force;Chou;JAMA,2022

3. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?;Christians;Pharmacol Ther,1998

4. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update;Mancini;Can J Cardiol,2013

5. Statin intolerance clinical guide 2018;Kajinami;J Atherosclerosis Thromb,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeled Hepatic/Plasma Exposures of Omeprazole Prescribed Alone in Cytochrome P450 2C19 Poor Metabolizers Are Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database;Biological and Pharmaceutical Bulletin;2024-05-24

2. Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome <i>P450 2C9*3</i> as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database;Biological and Pharmaceutical Bulletin;2024-03-15

3. Identification and Functional Assessment of EightCYP3A4Allelic Variants*39–*46Detected in the Chinese Han Population;Drug Metabolism and Disposition;2024-01-09

4. Time-to-onset Analysis of Rhabdomyolysis due to Different Proton Pump Inhibitors Using a Pharmacovigilance Database;In Vivo;2024

5. Pharmacokinetic Models Scaled Up from Humanized Liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated andN-Demethylated Metabolites in Pediatric Patients Genotyped for CytochromeP450 2D6;Drug Metabolism and Disposition;2023-10-25